Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.76 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.76 |
| ▸ | CTSD | P07339 | 3/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934833 | 0.92 | BACE1 (0.79) | BACE1BACE2CTSD | |
| SCHEMBL17296543 | 0.86 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL15783579 | 0.86 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL15986218 | 0.86 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL1935932 | 0.86 | BACE1 (0.73) | BACE1BACE2 | |
| SCHEMBL14733562 | 0.85 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL15630354 | 0.85 | BACE1 (1.00) | BACE1BACE2CTSDKCNH2 | |
| SCHEMBL15783577 | 0.83 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL15369962 | 0.83 | BACE1 (0.61) | BACE1BACE2CTSD | |
| SCHEMBL15986147 | 0.83 | BACE1 (1.00) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751116-B1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2016-10-12 | — | — | EP | claimed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | claimed |
| EP-2751116-B1 | HEXAHYDROPYRANO [3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2016-10-12 | — | — | EP | disclosed |
| US-8933221-B2 | Hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | BRODNEY MICHAEL AARON (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053373-A1 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | DPYD, TPMT, QDPR | BACE1 3093/4885BACE2 2953/4885CTSD 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.